RELATIONSHIP BETWEEN SARCOPENIA AND METABOLIC SYNDROME


Creative Commons License

Küçükdağlı P., Bahat-Öztürk G., Kılıç C., İlhan B., Karan M. A.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2017), Florence, Italy, 23 - 26 March 2017, pp.539

  • Publication Type: Conference Paper / Summary Text
  • City: Florence
  • Country: Italy
  • Page Numbers: pp.539
  • Istanbul University Affiliated: Yes

Abstract

Objectives: Sarcopenia is a prevalent problem in the older population that is commonly considered for its well known adverse functional associations. Cardiovascular diseases and metabolic syndrome are also significant problems whose prevalence dramatically increase with age and remain the main cause of mortality in older adults. These two entities have recently been suggested to be inter-related and significant evidence has accumulated. Previous studies showed conflicting results which may depend on the differences in methodology assessing sarcopenia. In this study, we aimed to investigate the association between sarcopenia and metabolic syndrome components in terms of different sarcopenia methodologies.

Methods: Community dwelling older outpatients were prospectively recruited from the geriatrics outpatient clinics of a university hospital for assessing hand grip strength and gait speed. Body composition was assessed by bioimpedance analysis. Muscle strengthwas assessedmeasuring hand grip strengthwith a Jamar hand dynamometer.We used Turkish population cut-off points according to Baumgartner, Janssen and FNIHa-b definitions while assessing sarcopenia. The cut-off thresholds for muscle mass were defined as the mean-2SD of the values of the young reference study population. Low muscle mass was defined as followings according to Baumgartner, Janssen and FNIHa-b, respectively: appendicular muscle mass/height2 (kg/m2), skeletal muscle mass/total body weight*100 (%), muscle mass/body mass index (kg/m2). Hypertension (HT), diabetes mellitus (DM) and increased waist circumference (IWC) (Male–Female ≥102 cm vs. 88 cm, respectively) were used as the components of metabolic syndrome.

Results: Total of 970 community-dwelling outpatients between 60 and 99 years of age. 303 (31.2%) were male and 667 (68.8%) were female. Mean age was 75±7.2 years. N=19 (%2), n=449 (%46,2), n=601 (%61,9), n=178 (%18,3) of total had lower muscle-mass according to Baumgartner, Janssen and FNIHa-b, respectively. N=309 (%31.8) had lower gait speed, 363 (%37.4) had lower muscle strength, 479 (%49.3) had decreased muscle functionality. Sarcopenia prevalences were 11 (%1,2), 220 (%22,6), 315 (%32,4), 106 (%10,9) according to Baumgartner, Janssen and FNIHa-b, respectively. Prevalences of HT, DM, increased WC were 25.3%, 75%, 65.6% respectively. In chisquare analyses, lower-muscle-mass was associated with increased HT and WC according to Janssen and FNIHa methodology (p <0.05), while associated with only increased WC according to FNIHb methodology (p <0.001). According to Baumgartner methodology there was reverse-association between lower-muscle-mass and increased HT (p=0.055) and WC (p <0.001). In functional parameters only decreased gait speed was associated with increased WC in MS components (p=0.03). According to Janssen methodology increased HT and WC were associated with sarcopenia (p=0.04 and p <0.001, respectively) while FNIHa-b methodology was associated with only increased WC (p <0.001). Baumgartner methodology showed that sarcopenia is reverse associated with increased WC(p=0.001). There was no association between DMand lower-muscle-mass, gait speed, muscle strength and sarcopenia.

Conclusion: We observed that relationship between sarcopenia and MS depends on the kind of definition in sarcopenia. It seems that Janssen methodology has the highest prediction value in terms of MS in older population.